洛铂联合紫杉醇治疗晚期非小细胞肺癌近期疗效和安全性分析

目的观察评价洛铂(LBP)联合紫杉醇(PTX)治疗晚期非小细胞肺癌的有效性和安全性。方法 LBP联合PTX方案治疗晚期非小细胞肺癌30例,PTX 175 mg/m^2静滴,第1天,LBP 30mg/m^2,静滴,第2天,21天为1个周期。结果全组30例均至少完成2个周期化疗,均可评价疗效,获CR 1例,PR 10例,SD 13例,PD 6例,RR为36.6%,疾病控制率DCR CR+PR+NC为80.0%,主要不良反应为骨髓抑制,其中Ⅲ～Ⅳ度白细胞减少发生率为16.7%,非血液学毒性较轻微,可以耐受。结论 LBP联合PTX组成方案治疗初治的晚期NSCLC的疗效较好,毒性反应可以耐受。

Objective To evaluate the efficacy and toxicities of the combination of paclitaxel plus labap latin in the treatment of advanced non-small cell lung cancer(NSCLC ).Methods 30 patients with advanced NSCLC were accepted the protocol of TP.Results In 30 patients,1 case CR,10 cases PR,13 cases NC,6 cases PD,the overall response rate was 36.6%.disease control rate was 80.0%,the main side-effects were marrow suppression(the rate of gradeⅢandⅣwas 16.7%,),the non-hematology toxicity was slight.might be toleranted.Conclusion The combination therapy of paclitaxel plus labap latin could be the ideal chemotherapy protocol for patients with advanced NSCLC.